000155430 001__ 155430
000155430 005__ 20250415100045.0
000155430 0247_ $$2doi$$a10.1007/s00259-021-05253-y
000155430 0247_ $$2pmid$$apmid:33677733
000155430 0247_ $$2pmc$$apmc:PMC8175325
000155430 0247_ $$2ISSN$$a0340-6997
000155430 0247_ $$2ISSN$$a1432-105X
000155430 0247_ $$2ISSN$$a1619-7070
000155430 0247_ $$2ISSN$$a1619-7089
000155430 0247_ $$2altmetric$$aaltmetric:101492017
000155430 037__ $$aDZNE-2021-00636
000155430 041__ $$aEnglish
000155430 082__ $$a610
000155430 1001_ $$0P:(DE-HGF)0$$aAshton, N. J.$$b0
000155430 245__ $$aThe validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers.
000155430 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2021
000155430 3367_ $$2DRIVER$$aarticle
000155430 3367_ $$2DataCite$$aOutput Types/Journal article
000155430 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744633299_21648$$xReview Article
000155430 3367_ $$2BibTeX$$aARTICLE
000155430 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155430 3367_ $$00$$2EndNote$$aJournal Article
000155430 520__ $$aThe development of blood biomarkers that reflect Alzheimer's disease (AD) pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests for dementia differential diagnosis and early detection. In 2019, the Geneva AD Biomarker Roadmap Initiative included blood biomarkers in the systematic validation of AD biomarkers.A panel of experts convened in November 2019 at a two-day workshop in Geneva. The level of maturity (fully achieved, partly achieved, preliminary evidence, not achieved, unsuccessful) of blood biomarkers was assessed based on the Biomarker Roadmap methodology and discussed fully during the workshop which also evaluated cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers.Plasma p-tau has shown analytical validity (phase 2 primary aim 1) and first evidence of clinical validity (phase 3 primary aim 1), whereas the maturity level for Aβ remains to be partially achieved. Full and partial achievement has been assigned to p-tau and Aβ, respectively, in their associations to ante-mortem measures (phase 2 secondary aim 2). However, only preliminary evidence exists for the influence of covariates, assay comparison and cut-off criteria.Despite the relative infancy of blood biomarkers, in comparison to CSF biomarkers, much has already been achieved for phases 1 through 3 - with p-tau having greater success in detecting AD and predicting disease progression. However, sufficient data about the effect of covariates on the biomarker measurement is lacking. No phase 4 (real-world performance) or phase 5 (assessment of impact/cost) aim has been tested, thus not achieved.
000155430 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000155430 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155430 650_7 $$2Other$$aAlzheimer’s disease
000155430 650_7 $$2Other$$aAβ40
000155430 650_7 $$2Other$$aAβ42
000155430 650_7 $$2Other$$aBlood
000155430 650_7 $$2Other$$aP-tau
000155430 650_7 $$2Other$$aStrategic roadmap
000155430 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000155430 650_7 $$2NLM Chemicals$$aBiomarkers
000155430 650_7 $$2NLM Chemicals$$aPeptide Fragments
000155430 650_7 $$2NLM Chemicals$$atau Proteins
000155430 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000155430 650_2 $$2MeSH$$aAmyloid beta-Peptides
000155430 650_2 $$2MeSH$$aBiomarkers
000155430 650_2 $$2MeSH$$aHumans
000155430 650_2 $$2MeSH$$aPeptide Fragments
000155430 650_2 $$2MeSH$$aTomography, X-Ray Computed
000155430 650_2 $$2MeSH$$atau Proteins
000155430 7001_ $$aLeuzy, A.$$b1
000155430 7001_ $$aKarikari, T. K.$$b2
000155430 7001_ $$aMattsson-Carlgren, N.$$b3
000155430 7001_ $$aDodich, A.$$b4
000155430 7001_ $$0P:(DE-2719)9000492$$aBoccardi, M.$$b5
000155430 7001_ $$aCorre, J.$$b6
000155430 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b7
000155430 7001_ $$aNordberg, A.$$b8
000155430 7001_ $$aOssenkoppele, R.$$b9
000155430 7001_ $$aZetterberg, H.$$b10
000155430 7001_ $$aBlennow, K.$$b11
000155430 7001_ $$0P:(DE-2719)9001538$$aFrisoni, Giovanni B$$b12$$udzne
000155430 7001_ $$aGaribotto, V.$$b13
000155430 7001_ $$aHansson, O.$$b14
000155430 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-021-05253-y$$gVol. 48, no. 7, p. 2140 - 2156$$n7$$p2140 - 2156$$tEuropean journal of nuclear medicine and molecular imaging$$v48$$x1619-7089$$y2021
000155430 8564_ $$uhttps://pub.dzne.de/record/155430/files/DZNE-2021-00636.pdf$$yOpenAccess
000155430 8564_ $$uhttps://pub.dzne.de/record/155430/files/DZNE-2021-00636.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155430 909CO $$ooai:pub.dzne.de:155430$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000155430 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000492$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000155430 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811239$$aExternal Institute$$b7$$kExtern
000155430 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001538$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000155430 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155430 9132_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000155430 9141_ $$y2021
000155430 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000155430 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-23
000155430 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155430 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2021$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEUR J NUCL MED MOL I : 2021$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000155430 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-02$$wger
000155430 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155430 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-23
000155430 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-23
000155430 9201_ $$0I:(DE-2719)5000062$$kAG Boccardi$$lImplementation Neuroscience$$x0
000155430 9201_ $$0I:(DE-2719)6000017$$kRostock / Greifswald common$$lRostock / Greifswald common$$x1
000155430 980__ $$ajournal
000155430 980__ $$aVDB
000155430 980__ $$aUNRESTRICTED
000155430 980__ $$aI:(DE-2719)5000062
000155430 980__ $$aI:(DE-2719)6000017
000155430 9801_ $$aFullTexts